Statistics for A Phase 2 Study of Dasatinib in Recurrent Clear Cell Carcinoma of the Ovary, Fallopian Tube, Peritoneum or Endometrium: NRG Oncology/Gynecologic Oncology Group Study 0283

Total visits

views
A Phase 2 Study of Dasatinib in Recurrent Clear Cell Carcinoma of the Ovary, Fallopian Tube, Peritoneum or Endometrium: NRG Oncology/Gynecologic Oncology Group Study 0283 0

Total visits per month

views
May 2024 0
June 2024 0
July 2024 0
August 2024 0
September 2024 0
October 2024 0
November 2024 0